Xenon Pharmaceuticals

Biotech · Public

Small molecule selective Kv7 potassium channel opener (azetukalner) for neurological disorders

xenon-pharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
14 granted · 26 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1175Unleash Immuno Oncolytics, Inc.—$3.0M
1176Cessation Therapeutics, Inc.—$6.8M
1177Dnalite Therapeutics, Inc.—$5.6M
1178Xenon Pharmaceuticals——
1179Pagari Life Science Corp.—$678K
1180PRIMAL THERAPIES, INC.—$677K
1181Grace Bio-Labs, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 14 granted of 40
  • Methods Of Administering A Voltage-gated Potassium Channel Openerapplication
  • Method For Treating Epilepsygranted
  • Methods For Enhancing The Bioavailability And Exposure Of A Voltage-gated Potassium Channel Openerapplication
  • Methods For Enhancing The Bioavailability And Exposure Of A Voltage-gated Potassium Channel Openerapplication
  • Pyridinylacetamide Derivatives As Sodium Channel Activatorsapplication
  • Methods And Uses For Treating Anhedoniaapplication
  • Solid State Crystalline Forms Of A Selective Potassium Channel Modulatorgranted
  • Pyridinyl Derivatives As Sodium Channel Activatorsapplication
  • Methods Of Treating Depressive Disordersapplication
  • Pyridine Derivatives And Their Use As Sodium Channel Activatorsapplication
  • Methods Of Treating Depressive Disordersgranted
  • Conjoint Therapy For Treating Seizure Disordersapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.